SGRY Q1 Deep Dive: Stable Margins and Physician Recruitment Offset Volume Headwinds

Healthcare company Surgery Partners (NASDAQ:SGRY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.5% year on year to $810.9 million. The company expects the full year’s revenue to be around $3.4 billion, close to analysts’ estimates. Its non-GAAP loss of $0.03 per share was 77.8% above analysts’ consensus estimates.

Is now the time to buy SGRY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Surgery Partners’ first quarter saw revenue growth above Wall Street expectations, with management attributing performance to stability across its surgical facilities and initial recovery in previously pressured hospital markets. CEO Eric Evans highlighted ongoing improvements in operational consistency and the company’s focus on higher-acuity procedures. The company also navigated short-term headwinds from weather-related disruptions in lower-acuity markets, which tempered overall case volume. Evans emphasized the strategic benefit of recent investments in surgical robotics and the continued expansion of musculoskeletal (MSK) services as key factors supporting the quarter’s results.

Looking forward, Surgery Partners’ full-year guidance is centered on executing its organic growth strategy, accelerating physician recruitment, and driving operational efficiency. Management stated that cost containment and margin improvement are priorities, as pressure from provider taxes and payer mix shifts is expected to persist. COO Justin Oppenheimer, new to the leadership team, is focused on enhancing operational execution and supporting physician partners, which management believes will unlock embedded earnings potential. Evans noted that ongoing portfolio optimization, including potential asset sales, is expected to improve free cash flow and reduce leverage over the coming quarters.

Key Insights from Management’s Remarks

Management pointed to progress in portfolio stability, higher-acuity case mix, and disciplined cost control as central to the quarter’s performance. Key business updates included advancements in robotics, physician recruiting, and de novo facility expansion.

• MSK and Robotics Expansion: Surgery Partners saw a 14.6% year-over-year increase in total joint procedures within its ambulatory surgery centers (ASCs), driven by continued investment in surgical robotics. The company now operates 73 surgical robots, which management believes help attract physicians and support a shift toward higher-acuity cases.
• Physician Recruitment Momentum: The company recruited approximately 140 new physicians during the quarter, with a strong focus on orthopedics, ophthalmology, and gastrointestinal specialties. Management views this as a critical lever for accelerating both volume and acuity in the business, though they note new recruits take time to ramp up.
• De Novo Facility Growth: One new de novo ASC opened in the quarter, bringing the total to nine over the past twelve months. These new centers are heavily weighted toward musculoskeletal procedures and are expected to contribute to long-term growth once they mature and reach breakeven.
• Cost Management Initiatives: Management reported sequential improvement in labor and supply costs as a percentage of revenue, partially offsetting pressures from provider taxes and incentive compensation. CFO David Doherty noted that cost discipline will remain a key focus to protect margins, especially as provider tax headwinds continue.
• Portfolio Optimization Progress: Advanced discussions are underway to divest non-core surgical hospital assets, with management targeting an announcement in mid-2026. The aim is to simplify operations, improve free cash flow, and accelerate deleveraging. Evans emphasized that this initiative, if completed, would support long-term margin expansion and strategic focus on the core ASC business.

Drivers of Future Performance

Surgery Partners’ outlook for the remainder of the year is grounded in physician recruitment, MSK case growth, and continued margin discipline, while acknowledging ongoing cost and payer mix headwinds.

• Physician Recruitment and Case Growth: Management expects net new physician additions to gradually drive higher surgical volumes and a continued shift toward higher-acuity, higher-margin cases, particularly in musculoskeletal specialties. The pace of new physician onboarding and their transition to productivity remain key variables.
• Cost Containment and Margin Focus: Operational efficiency initiatives, including labor and supply cost management, are expected to partially offset ongoing headwinds such as provider taxes and payer mix shifts. Management has identified further opportunities for working capital improvement and continues to emphasize expense discipline as necessary for margin stability.
• Portfolio Optimization and M&A Pipeline: The company is advancing divestitures of certain surgical hospital assets to streamline its portfolio and improve free cash flow. While M&A activity was modest in the first quarter, management expects deal flow to be weighted toward the back half of the year, with any completed transactions representing upside to current guidance.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will monitor (1) the pace and productivity of new physician onboarding and their impact on case volume, (2) successful execution and timing of portfolio optimization or asset divestitures, and (3) sustained progress in cost containment to protect margins against persistent provider tax and payer mix pressures. Additional attention will be given to the ramp-up of new de novo centers and the potential for increased M&A activity later in the year.

Surgery Partners currently trades at $15.02, up from $14.20 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.